SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

New directions for deep learning in cancer research through concept explainability and virtual experimentation.

NADIR aims to enhance deep learning in cancer research by integrating biological knowledge to extract concepts and verify mechanisms, focusing on tumor-immune interactions in colorectal and gastric cancer.

Subsidie
€ 1.498.750
2024

Projectdetails

Introduction

Deep learning (DL) is rapidly transforming cancer research and oncology. DL can extract subtle visual features from preclinical and clinical image data. In my junior research group, I have developed end-to-end DL methods to predict molecular biomarkers and clinical outcomes directly from histopathology slides.

Availability of Histopathology Slides

Because histopathology slides are ubiquitously available for any patient with a solid tumor, DL is a broad tool for translational studies. It enables researchers to extract molecular information and make predictions about clinical outcomes.

Limitations of Deep Learning

However, the potential of DL in cancer research is fundamentally limited because it is purely descriptive and, in many cases, a black-box system. Additionally, DL is currently disjoint from the vast amount of biological mechanistic knowledge in cancer research and from the world of experimentation.

Addressing the Gap

In NADIR, I will close this gap. My hypothesis is that DL models can not only make predictions but can also be used to verify existing biological knowledge and to make new mechanistic discoveries.

Tools and Methodology

The main tools that allow me to address this are:

  1. Concept explainability
  2. Counterfactual virtual experimentation

For both, there exists a non-medical proof of concept, but no systematic biomedical application yet.

Research Approach

I approach this problem as a biomedical cancer researcher with training in programming, medical image analysis, and biomedical engineering. As such, I will develop DL systems that can:

  • Extract biological concepts
  • Elucidate biological mechanisms
  • Create and answer mechanistic hypotheses

Synergy with Other Research Pipelines

NADIR’s tools will be synergistic with and can be used together with other biological high-throughput experimentation pipelines, such as:

  • Transgenic animal experiments
  • Tumor organoid cultures

Focus Area and Outreach

The main use case of NADIR is focused on tumor-immune interaction in colorectal and gastric cancer. Through the educational and outreach program in NADIR, it will be made available as a general tool for cancer researchers in biomedicine.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.498.750
Totale projectbegroting€ 1.498.750

Tijdlijn

Startdatum1-1-2024
Einddatum31-12-2028
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • TECHNISCHE UNIVERSITAET DRESDENpenvoerder

Land(en)

Germany

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Foundation models for molecular diagnostics - machine learning with biological ‘common sense’

FoundationDX aims to enhance molecular diagnostics by using self-supervised learning on diverse biomolecular data to accurately predict cancer subtypes and treatment outcomes without extensive labeled datasets.

ERC Consolid...€ 2.000.000
2024
Details

Interpretable Artificial Intelligence across Scales for Next-Generation Cancer Prognostics

This project aims to enhance cancer prognosis and treatment selection by applying advanced machine learning to whole-slide images, addressing key knowledge gaps and improving model explainability.

ERC Starting...€ 1.494.810
2022
Details

Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI

Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.

ERC Starting...€ 1.497.669
2024
Details

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.

ERC Consolid...€ 1.993.875
2023
Details

Deep learning derived mechanical biomarkers for cancer therapy prediction

This project aims to develop a deep learning-based biomarker using ultrasound elastography to predict and monitor cancer treatment responses, particularly targeting tumor stiffness in sarcoma patients.

ERC Proof of...€ 150.000
2022
Details
ERC Consolid...

Foundation models for molecular diagnostics - machine learning with biological ‘common sense’

FoundationDX aims to enhance molecular diagnostics by using self-supervised learning on diverse biomolecular data to accurately predict cancer subtypes and treatment outcomes without extensive labeled datasets.

ERC Consolidator Grant
€ 2.000.000
2024
Details
ERC Starting...

Interpretable Artificial Intelligence across Scales for Next-Generation Cancer Prognostics

This project aims to enhance cancer prognosis and treatment selection by applying advanced machine learning to whole-slide images, addressing key knowledge gaps and improving model explainability.

ERC Starting Grant
€ 1.494.810
2022
Details
ERC Starting...

Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI

Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.

ERC Starting Grant
€ 1.497.669
2024
Details
ERC Consolid...

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.

ERC Consolidator Grant
€ 1.993.875
2023
Details
ERC Proof of...

Deep learning derived mechanical biomarkers for cancer therapy prediction

This project aims to develop a deep learning-based biomarker using ultrasound elastography to predict and monitor cancer treatment responses, particularly targeting tumor stiffness in sarcoma patients.

ERC Proof of Concept
€ 150.000
2022
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

AI-based medical assistant - Herkennen en classificeren van tumoren m.b.v. kunstmatige intelligentie

Dit project ontwikkelt een geavanceerde beeldherkenningstechnologie voor realtime screening van eiwittypologieën in biopten, om de behandeling van complexe tumoren te verbeteren.

Mkb-innovati...€ 200.000
2018
Details

Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients

DoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually.

EIC Accelerator€ 2.499.999
2024
Details

Artificiële intelligentie voor Reproduceerbare Analyse van Tumorgroei

Het project ontwikkelt AI-software voor betrouwbare tumorweefselanalyse, gericht op CE-certificering voor de Europese markt.

1.1 - RSO1.1...€ 373.158
2023
Details

Enabling the transition to 3D digital pathology

3DPATH aims to develop a clinically viable 3D tissue scanner using advanced light-sheet fluorescence microscopy to enhance histopathology accuracy and improve patient care globally.

EIC Transition€ 2.493.683
2025
Details
Mkb-innovati...

AI-based medical assistant - Herkennen en classificeren van tumoren m.b.v. kunstmatige intelligentie

Dit project ontwikkelt een geavanceerde beeldherkenningstechnologie voor realtime screening van eiwittypologieën in biopten, om de behandeling van complexe tumoren te verbeteren.

Mkb-innovatiestimulering Topsectoren R&D Samenwerking
€ 200.000
2018
Details
EIC Accelerator

Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients

DoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually.

EIC Accelerator
€ 2.499.999
2024
Details
1.1 - RSO1.1...

Artificiële intelligentie voor Reproduceerbare Analyse van Tumorgroei

Het project ontwikkelt AI-software voor betrouwbare tumorweefselanalyse, gericht op CE-certificering voor de Europese markt.

1.1 - RSO1.1.: Ontwikkelen en versterken van de onderzoeks- en innovatiecapaciteit en invoeren van geavanceerde technologieën
€ 373.158
2023
Details
EIC Transition

Enabling the transition to 3D digital pathology

3DPATH aims to develop a clinically viable 3D tissue scanner using advanced light-sheet fluorescence microscopy to enhance histopathology accuracy and improve patient care globally.

EIC Transition
€ 2.493.683
2025
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.